Fmr LLC Innoviva, Inc. Transaction History

Fmr LLC

$1.59 Trillion
Q3 2024

A detailed history of Fmr LLC transactions in Innoviva, Inc. stock. As of the latest transaction made, Fmr LLC holds 10,119 shares of INVA stock, worth $205,618. This represents 0.0% of its overall portfolio holdings.

Number of Shares

10,119

Previous 9,348 8.25%

Holding current value

$205,618

Previous $153,000 27.45%

% of portfolio

0.0%

Previous 0.0%

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	BUY	$16.33 - $20.04 $12,590 - $15,450	771 Added 8.25%	10,119 $195,000
Q2 2024 Aug 13, 2024	BUY	$14.4 - $16.4 $10,771 - $12,267	748 Added 8.7%	9,348 $153,000
Q1 2024 May 13, 2024	BUY	$14.56 - $16.78 $17,195 - $19,817	1,181 Added 15.92%	8,600 $131,000
Q4 2023 Feb 13, 2024	BUY	$12.32 - $16.27 $7,552 - $9,973	613 Added 9.01%	7,419 $119,000
Q3 2023 Nov 13, 2023	SELL	$12.37 - $13.89 $2,461 - $2,764	-199 Reduced 2.84%	6,806 $88,000
Q2 2023 Aug 11, 2023	BUY	$11.39 - $13.72 $17,802 - $21,444	1,563 Added 28.72%	7,005 $89,000
Q1 2023 May 11, 2023	BUY	$10.73 - $13.6 $25,118 - $31,837	2,341 Added 75.49%	5,442 $61,000
Q4 2022 Feb 13, 2023	BUY	$11.8 - $13.78 $613 - $716	52 Added 1.71%	3,101 $41,000
Q3 2022 Nov 10, 2022	BUY	$11.61 - $15.22 $2,914 - $3,820	251 Added 8.97%	3,049 $36,000
Q2 2022 Aug 12, 2022	SELL	$14.32 - $19.88 $4,152 - $5,765	-290 Reduced 9.39%	2,798 $41,000
Q1 2022 May 13, 2022	BUY	$15.39 - $20.25 $33,196 - $43,679	2,157 Added 231.69%	3,088 $60,000
Q4 2021 Feb 14, 2022	SELL	$15.91 - $18.72 $15 - $18	-1 Reduced 0.11%	931 $16,000
Q3 2021 Nov 15, 2021	BUY	$13.06 - $17.24 $5,315 - $7,016	407 Added 77.52%	932 $15,000
Q2 2021 Aug 13, 2021	BUY	$11.45 - $13.96 $6,011 - $7,329	525 New	525 $7,000

Others Institutions Holding INVA

# of Institutions

225

Shares Held

78.3M

Call Options Held

20K

Put Options Held

5.4K

View Full List

About Innoviva, Inc.

Ticker INVA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 69,706,000
Market Cap $1.42B
Description
Innoviva, Inc. engages in the development and commercialization of pharmaceuticals in the United States and internationally. Its products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a ...

More about INVA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Fmr LLC, based on Form 13F filings with the SEC.

News

Stay updated on Fmr LLC with notifications on news.

Account